Today marks 5 years since medical cannabis was rescheduled in the UK, making it available for eligible patients. A lot of progress has been made, with thousands of patients in receipt of a medical cannabis prescription, but there is still a lot of work to do and the lack of high-quality clinical evidence continues to be a barrier to wider patient access and awareness. While we continue to call for government funding into clinical trials, our bank of real-world evidence is growing, thanks to the thousands of UK patients contributing to the UK Medical Cannabis Registry, now the world’s largest database of patient reported health outcomes.
Patients who are signed up to the Curaleaf Access Scheme also receive reduced consultation fees when contributing to the UK Medical Cannabis Registry. Since last year’s anniversary, we’ve used this invaluable data to publish a further 10 research papers on topics such as fibromyalgia, anxiety, and depression. These findings are invaluable and are used by our team at Sapphire to inform and improve how the medicine is prescribed, but we also believe that it can help drive awareness and understanding, whilst promoting a better understanding of its therapeutic applications.
Click here to find the latest medical cannabis research HERE
